Post
CMS mandates registry data for coverage of Alzheimer’s drugs
The Centers for Medicare and Medicaid Services’ (CMS) Administrator Chiquita Brooks-LaSure announced that Eisai’s Leqembi (lecanemab) will be covered under …
Novartis touts breast cancer win with “landmark” Kisqali results
Kicking off this year's American Society of Clinical Oncology's (ASCO) conference, Novartis has released data supporting the use of its …
Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly
The European Commission (EC) and Pfizer/BioNTech have agreed to amend their current supply contract to deliver Covid-19 vaccines to the …
AB Science announces Canadian patent for masitinib to treat ALS
AB Science has secured a Canadian patent for its lead compound masitinib to treat amyotrophic lateral sclerosis (ALS), a fatal …
EC approves Briumvi to treat relapsing forms of multiple sclerosis
The European Commission (EC) has approved TG Therapeutics’ Briumvi (ublituximab-xiiy) to treat relapsing forms of multiple sclerosis (RMS) in adult …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Anavex Life Sciences receives US patent for ANAVEX 2-73 (blarcamesine)
Anavex Life Sciences has secured new US intellectual property compositions patent for its ANAVEX 2-73 (blarcamesine). The patent number 11,661,405 has …
Swiss company Lonza acquires Synaffix to boost ADC offering
Switzerland-based company Lonza has boosted its antibody-drug conjugates (ADCs) offering with the acquisition of Dutch biotechnology company Synaffix for a …
Rentschler Biopharma and Ikarovec partner to expedite new gene therapies
Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s …
China’s NMPA approves Vascepa for hypertriglyceridemia
China’s National Medical Products Administration (NMPA) has granted regulatory approval to Amarin’s commercial partner EddingPharm (EDDING) for Vascepa (icosapent ethyl). Vascepa …
Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial
Sanofi has announced that its anti-CD40L antibody frexalimab demonstrated significantly reduced disease activity in a Phase II trial of patients …
AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer
The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD’s Lynparza (olaparib), with standard therapies …
Pneumagen raises £8 million for further study of intranasal antiviral
Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies …
InDex Pharmaceuticals signs licence deal with Viatris for cobitolimod
InDex Pharmaceuticals has entered a licence deal with Viatris Pharmaceutical Japan for the development and commercialisation of cobitolimod in Japan …
Algernon announces acceptance of Repirinast patent application in Japan
Algernon Pharmaceuticals’ patent application for NP-251 (Repirinast) has been accepted by the Japanese Patent Office (JPO) for the treatment of …
Negative FDA AdCom vote for Intercept’s obeticholic acid in NASH
On 19 May, the FDA’s Gastrointestinal Drugs Advisory Committee (GDAC), by a vote of 12 to two, with two abstentions, …